摘要 |
The use of a pharmaceutically acceptable cholinesterase inhibitor or a prodr ug therefor for counteracting the sedative, hypnotic or respiratory depressive effects of benzodiazepines; substantially without interfering with, the anxiolytic, antipsychotic, anticonvulsant; and muscle relaxant activity of benzodiazepines, especially, the benzodiazepines used for treatment of diseases where the sedative; hypnotic or respiratory depressive effects are undesirable, such as diseases selected from the group consisting of anxiety, anxiety neurosis; anxiety reactions, panic reactions, schizophrenia; affective or schizoaffective type schizophrenia, borderline psychosis, agitating endogene depressions, hyperactivity in children, and muscle spasms; the use of a pharmaceutically acceptable cholinesterase inhibitor or a prodrug therefor for the treatment of schizophrenia, in particular affective or schizoaffective type shizophrenia. The acetyl cholinesterase is preferably o ne that acts substantially selectivity at nicotinic receptor sites, and which has selectively for acetyl cholinesterase opposed to butyryl cholinesterase, e.g. galanthamine or a galanthamine derivative.
|